Anthera Pharmaceuticals Inc. (ANTH) Upgraded to Hold by Zacks Investment Research
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
ANTH has been the topic of a number of other research reports. Jefferies Group restated a buy rating on shares of Anthera Pharmaceuticals in a report on Wednesday, August 10th. HC Wainwright assumed coverage on shares of Anthera Pharmaceuticals in a report on Friday, July 8th. They issued a buy rating and a $10.00 target price on the stock. Finally, FBR & Co restated a hold rating on shares of Anthera Pharmaceuticals in a report on Monday, June 20th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $8.70.
Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 3.13 on Tuesday. The company’s 50 day moving average price is $3.10 and its 200 day moving average price is $3.34. The firm’s market cap is $129.67 million. Anthera Pharmaceuticals has a 52-week low of $2.28 and a 52-week high of $7.15.
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.04. Anthera Pharmaceuticals had a negative return on equity of 131.24% and a negative net margin of 1,273.45%. Analysts predict that Anthera Pharmaceuticals will post ($1.37) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in Anthera Pharmaceuticals by 17.6% in the first quarter. Franklin Resources Inc. now owns 3,197,712 shares of the biopharmaceutical company’s stock valued at $11,576,000 after buying an additional 479,700 shares during the period. Wexford Capital LP acquired a new position in Anthera Pharmaceuticals during the first quarter valued at approximately $256,000. State Street Corp increased its position in Anthera Pharmaceuticals by 6.6% in the first quarter. State Street Corp now owns 556,307 shares of the biopharmaceutical company’s stock valued at $2,014,000 after buying an additional 34,225 shares during the period. Geode Capital Management LLC increased its position in Anthera Pharmaceuticals by 1.0% in the first quarter. Geode Capital Management LLC now owns 242,004 shares of the biopharmaceutical company’s stock valued at $876,000 after buying an additional 2,295 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its position in Anthera Pharmaceuticals by 371.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 68,300 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 53,800 shares during the period. 55.24% of the stock is owned by institutional investors.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.